Description: Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Home Page: www.theranexus.com
60 avenue Rockefeller
Lyon,
69008
France
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Franck Mouthon | Chairman & CEO |
| Mr. Mathieu Charvériat | Chief Scientific Officer, Deputy CEO & Director |
| Mr. Thierry Lambert | CFO and Admin. & Financial Director |
| Ms. Francoise Vincent-Larrode | Director of HR |
| Mr. Julien Veys | Chief Bus. Devel. Officer |
| Ms. Marie Sebille | Chief Medical Officer |
Exchange: PA
Country: FR : France
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0553 |
| Price-to-Sales TTM: | 22.0833 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |